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QUALITY OF ANTICOAGULATION CONTROL IN PATIENTS
WITH ATRIAL FIBRILLATION MANAGED IN ROUTINE
MEDICAL CARE IN THE UNITED STATES
Ansell JE1, Caro JJ2, Proskorovsky I3, Lordan N2, Salas M2, Hauch O4,
Wygant G4, Hollowell J5, Bjorholt I6
1Boston Medical—Boston University, Boston, MA, USA; 2Caro
Research, Concord, MA, USA; 3Caro Research Institute, Dorval, QC,
Canada; 4AstraZeneca Pharmaceuticals LP, Wilmington, DE, USA;
5AstraZeneca R&D Mölndal, Mölndal, Sweden; 6Nordic Health
Economics Research AB, Hovas, Sweden
OBJECTIVE: To quantify the quality of anticoagulation control
in routine medical care in the US: Long-term oral anticoagula-
tion reduces the risk of ischemic stroke in atrial ﬁbrillation but
only if the international normalized ratio (INR) is tightly con-
trolled between two and three. METHODS: A cohort study was
carried out in practices with no staff dedicated to anticoagula-
tion in four states. Charts of patients 18 years or older with atrial
ﬁbrillation and on an anticoagulant at least 60 consecutive days
between July 1, 2001 and June 30, 2002 were reviewed by
trained abstractors based on a standard form that covered mon-
itoring tests, results and patient outcomes. Data were entered via
touch-tone telephone (IVRS) and sensitivity analyses were per-
formed. RESULTS: Charts of 686 patients from 11 practices
(most internal or family medicine) and 67 practitioners were
reviewed. Mean age was 75 years; 53% male; 79% received war-
farin and mean interval between INR tests was 25 ± 22 days;
52% of physicians gave occasional face-to-face consultations in
connection with INR tests and 78% used clinical judgment alone
to adjust anticoagulant dose. A total of 53% of charts speciﬁed
a target INR of 2–3; patients spent 42% of the time with INRs
out of this range, most (27%) too low, yet the anticoagulant dose
was adjusted only a third of the times that INRs were out of
range. CONCLUSION: Concerted efforts to improve anticoag-
ulation have been made for more than a decade. Nevertheless,
despite increasing costs with frequent INR testing, there remain
severe deﬁciencies in the routine management of anticoagulation
in the US.
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DATA CAPTURE VIA INTERACTIVE VOICE RESPONSE 
SYSTEM IN A NATIONAL STUDY OF ANTICOAGULATION
MANAGEMENT
Payne K1, Lordan N2, Caro JJ2, O’Brien J2
1Caro Research Institute, Dorval, QC, Canada; 2Caro Research
Institute, Concord, MA, USA
Electronic data capture and remote study monitoring are being
implemented more frequently instead of traditional paper format
data collection methods for clinical trials. In outcomes research,
electronic data capture is only beginning to be used; few studies
report on the efﬁciency and feasibility of this technique. OBJEC-
TIVE: To assess the use of a telephone-based interactive voice
response data entry system (IVRS) used in a national chart
review study of anticoagulation management. METHODS: Fol-
lowing a one day training, nurses abstracted chart data using a
68 question (mostly closed) paper questionnaire. Anonymized
data were entered into the study database using a password-
protected IVRS accessed using a nationwide toll-free telephone
number available round the clock. RESULTS: Data entered by
10 study nurses were 100% complete for all 686 subjects
enrolled at four study sites in four US States (CA, MA, IN, NC).
Site initiated data corrections occurr for only 5% of subjects.
Time from database lock to a clean dataset was 10 working days.
Mean data entry time per subject was 16 minutes (min = 1; max
= 20) or 14 seconds per question. Key IVRS features designed to
facilitate use (e.g., question repeat, invalid answer prompt and
automatic re-entry to last question answered when entry was
interrupted) all worked well. CONCLUSIONS: Data capture
and remote study monitoring using IVRS is an efﬁcient and accu-
rate means of collecting detailed health economic data with a
minimum of oversight.
CARDIOVASCULAR DISEASE—Congestive Heart
Failure/Heart Failure
PCV13
COST-EFFECTIVENESS EVALUATION OF EPLERENONE IN
PATIENTS WITH HEART FAILURE FOLLOWING AMI IN
GERMANY
Kvasz M1, Zhang Z2, Lenz C3, Mundhenke M3,Weintraub WS2
1Pﬁzer Inc, New York, NY, USA; 2Emory University, Atlanta, GA, USA;
3Pﬁzer Pharma GmbH, Karlsruhe, Germany
OBJECTIVE: The EPHESUS study demonstrated that aldos-
terone blockade with eplerenone decreased mortality in patients
with left ventricular systolic dysfunction (LVSD) and heart
failure after acute myocardial infarction (AMI). The EPHESUS
pharmacoeconomic analysis presented below was performed 
to evaluate the cost-effectiveness of eplerenone in the German
setting. METHODS: A total of 6632 patients with LVSD and
heart failure after AMI were randomized to eplerenone or
placebo and followed for a mean of 16-months. The co-primary
endpoints were all-cause death and the composite of cardiovas-
cular death/cardiovascular hospitalization. The evaluation of
resource use included hospitalizations, outpatient services, and
medications. Survival beyond the trial period was estimated
using data from the Framingham Heart Study, the Saskatchewan
Health database, and the Worcester Heart Attack Registry. The
incremental cost-effectiveness of eplerenone in cost per life-year
and quality-adjusted life-year gained was estimated. RESULTS:
The number of life-years gained with eplerenone was 0.1014
based on Framingham (95% CI: 0.0306–0.1740), 0.0636 with
Saskatchewan (95% CI: 0.0229–0.1038) and 0.1337 (95% CI:
0.0438–0.2252) with Worcester survival estimates. Total costs
were 961.2€ higher over the trial period in the eplerenone arm,
due to drug cost. The incremental cost-effectiveness ratio was
9,173€ per life-year gained with Framingham (98.8% under
50,000€ per-life year gained), 14,627.8€ with Saskatchewan, and
6,955.6€ with Worcester survival estimates. CONCLUSION:
Eplerenone is effective in reducing mortality and, in Germany, is
also cost-effective in increasing years of life for patients with
heart failure after AMI.
PCV14
MODELING THE ECONOMIC CONSEQUENCES OF CARDIAC
RESYNCHRONIZATION THERAPY IN THE UK
Caro JJ, Drummond TL
Caro Research, Concord, MA, USA
OBJECTIVE: To assess the economic implications of implanta-
tion with a cardiac resynchronization device (CRT) versus
optimum pharmacologic treatment (OPT) for NYHA class III or
IV heart failure. METHODS: A discrete event simulation of the
course of heart failure was used to compare 1000 pairs of iden-
tical patients—one receiving CRT, the other OPT—for two years,
in terms of hospitalizations for heart failure, device-related com-
plications, NYHA class, and QOL (mortality assumed equal). All
input rates were derived by speciﬁc analyses of the data obtained
in the Multicenter InSync Randomized Clinical Evaluation
(MIRACLE). Changes in NYHA class were translated to QOL
via the corresponding distributions of Minnesota Living with
Heart Failure scores and the related utilities. Direct medical costs
to the NHS, reported in 2002 British Pounds Sterling (£), dis-
265Abstracts
counted at 6%/yr, were obtained from HRG codes E18–19. Ben-
eﬁts were discounted at 1.5%. Extensive multivariate sensitivity
analyses were done. RESULTS: In these patients with mean age
of 64yrs, 91% in class III, 23% dead at two yrs, CRT reduced
hospitalization for heart failure by 42%, leading to total costs
of £3500 per patient vs. £3000 with OPT. Based on 100 repli-
cations, mean improvement of 0.16 QALY (SD 0.009) is
achieved with CRT at mean net cost of £526 (SD £167) per
patient, a mean cost-effectiveness ratio of £3379/QALY. Exten-
sive sensitivity analyses revealed the greatest cost/QALY vari-
ability when the length of stay for heart failure was varied ± 25%
(£562–£6354). CONCLUSION: Despite the cost of implanta-
tion, cardiac resynchronization therapy decreases hospitaliza-
tions and increases QOL sufﬁciently to be cost-effective in
treating advanced heart failure.
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POTENTIAL MEDICAL COST OFFSETS OF TREATMENT WITH
ISOSRBIDE DINITRATE PLUS HYDRALAZINE IN AFRICAN
AMERICANS WITH HEART FAILURE
Becker R1, Klingman D2
1ValueMedics Research, Chicago, IL, USA; 2ValueMedics, Falls Church,
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OBJECTIVE: Combination therapy with isosorbide dinitrate
and hydralazine was recently shown to signiﬁcantly improve
clinical and survival outcomes in African Americans with con-
gestive heart failure (CHF). The objective of this analysis was to
measure the potential economic impact of this combination in
the US African American population with CHF. METHODS:
The population of African Americans with heart failure was esti-
mated from US Census Bureau and US NCHS 2002 NHANES
data. We then aggregated and compared drug and hospital costs
over a 10-month period (the duration of the trial) under a com-
bination therapy scenario vs. a usual-care scenario. Costs were
calculated in 2004 USD from the payer perspective. Cost of the
generic combination drug regimen (40mg isosorbide dinitrate
and 75mg hydralazine, three times daily) was calculated using
the AWP. The rates of ﬁrst hospitalizations for treated and
untreated patients were drawn from the trial (24.4% of patients
without drug combination and 16.4% with drug combination).
Hospital costs were estimated based on Medicare reimbursement
rates for DRG 127. RESULTS: The use of the drug combination
resulted in a cost savings of over $270 million dollars for the
entire population (n = 800,097), or $338 per person receiving
the drug combination. Cost savings with the drug combination
were realized over a wide range of clinical and cost parameters
and assumptions. CONCLUSION: Usage of the isosorbide dini-
trate and hydralazine combination in African Americans with
heart failure can be expected to generate cost savings in addition
to the signiﬁcant clinical beneﬁts of the drug combination.
Further studies of the drug combination over longer time hori-
zons, brand pricing (including pricing for a yet-to-be-approved
combination pill), and consideration of other costs such as treat-
ment of adverse events and physician fees will give a more 
complete picture of the beneﬁts of the drug combination in this
population.
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INCREMENTAL EFFECTS OF CONCURRENT
PHARMACOTHERAPEUTIC REGIMENS FOR HEART FAILURE
ON HOSPITALIZATIONS AND COSTS
Skrepnek GH1,Abarca J1, Malone DC1,Armstrong EP1, Shirazi FM2,
Woosley RL2
1University of Arizona College of Pharmacy,Tucson, AZ, USA;
2University of Arizona College of Medicine,Tucson, AZ, USA
OBJECTIVE: To evaluate the incremental differences of concur-
rent and persistent use of angiotensin-converting enzyme (ACE)
inhibitors, beta-blockers, loop diuretics, and digoxin on the risk
of hospitalization and total costs with heart failure patients
enrolled in a managed care organization. METHODS: Retro-
spective database analysis of outpatients diagnosed with heart
failure within a managed care organization covering 350,000
lives from January 1, 1997 to December 31, 1999. Linear and
logistic regression models were used to examine the association
between treatment regimens and all-cause hospitalizations or
total direct medical costs after controlling for patient demo-
graphics, comorbidities, and other risk factors. RESULTS: Of the
1903 patients meeting inclusion and exclusion criteria, 33.2% 
(n = 615) were observed not to have received any ACE inhibitor,
beta-blocker, loop diuretic, digoxin, or angiotensin-receptor
blockers (ARB). Subsequent multivariate analyses indicated that
the associated risk of one year, all-cause hospitalization was 2.5
times higher (p < 0.01) for patients taking none of these med-
ications relative to the overall sample, followed by a 43.6%
higher total health care costs (p < 0.01). Patients receiving three
or more of the speciﬁc medications analyzed were associated
with signiﬁcant decreases in risk of one year all-cause hospital-
ization of approximately 80% (p < 0.01) and decreases in total
costs of approximately 70% (p < 0.01) relative to those utiliz-
ing no therapy. CONCLUSION: This analysis appears to indi-
cate that a substantial portion of heart failure patients may be
receiving suboptimal pharmacotherapeutic care, resulting in a
higher associated risk of hospitalization and increase in total
health care costs. Conversely, patients that were adherent with
concurrent medication therapies were associated with decreases
in both hospitalizations and total costs. The implications of this
research suggest that quality improvement initiatives seek to
identify and manage those not being treated or adherent to estab-
lished evidence-based care.
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CAREMARK CAREPATTERNS®HEART FAILURE HOME
MONITORING PROGRAM IMPROVES PARTICIPANTS’ HOME
MONITORING COMPLIANCE
Fensterheim LE1, Duff D2, Sellers Y2, Hu L1, Stine N1
1Caremark Inc, Northbrook, IL, USA; 2Caremark Inc, San Antonio,TX,
USA
Caremark has developed an in-home program that monitors
weight and symptoms using a telemonitoring device. The device
includes a special scale and telephone. A registered nurse 
monitors for any changes in the participant and further assesses
their condition. The goal of this program is to encourage par-
ticipants to weigh daily to recognize early symptoms and to
follow their physician. OBJECTIVE: To evaluate the effective-
ness of the CarePatterns heart failure home monitoring program.
METHODS: Participants were selected based on severity, not on
dialysis, not in any other monitoring program, not going out of
town, and fewer than 320 pounds. The objectives were to get
participants to meet selected benchmarks after 60 days. These
included daily weight taking, action plan, and when to call their
physician, no changes in weight or symptoms in prior 28 days,
and fewer than three Non-Compliance alerts in 28 days.
RESULTS: In total, 100 participants enrolled, 51% male 49%
female, mean age of 73. Seventy-seven individuals started daily
weight taking. A total of 54, or 71%, of these participants met
the graduation requirement. The retention rate for the CarePat-
terns Heart Failure program was 98% for the enrolled group and
80% for the non-enrolled group p < 0.05, 45 participants had
an alert, resulting in 16 doctor visits, two emergency room visits
and two hospitalizations, 32 participants did not have an alert.
